Skip to main content
    P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.90
    -0.13 (-4.46%)

    Market Cap: $255.49M

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Protalix Biotherapeutics Inc (PLX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Protalix Biotherapeutics (PLX) has a market cap of $255.49M and an enterprise value of $233.45M. Revenue grew 36.96% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 8.62% below the market cap, as cash exceeds debt.

    Market Cap$255.49M
    Enterprise Value$233.45M
    Latest price (Nov 17, 2026)$2.90

    Key Dates

    The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 16, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.59% in the quarter ended Sep 30, 2026 and grew 4.59% a year over 2 years.

    Shares Outstanding80.46M
    Shares Change (YoY)+1.48%
    Shares Change (QoQ)+0.59%
    Share Count Growth (2Y CAGR)+4.59%

    Valuation Ratios

    Sales and book value multiples are 2.8x and 2.9x.

    P/E Ratio11.6x
    Forward P/E11.9x
    P/S Ratio2.8x
    Forward P/S2.9x
    P/B Ratio2.9x
    P/FCF Ratio15.5x
    P/OCF Ratio14.6x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 7.7x EBITDA and 14.0x free cash flow.

    EV / Earnings11.4x
    EV / Sales2.8x
    EV / EBITDA7.7x
    EV / EBIT9.0x
    EV / FCF14.0x

    Price Statistics

    The stock is up 55.65% over 52 weeks and trades 7.41% above its 50-day average.

    Beta (1Y)1.06
    52-Week Change+55.65%
    1-Month Change+13.09%
    3-Month Change+23.19%
    6-Month Change+52.37%
    5-Year Change+129.20%
    10-Year Change-44.91%
    Total Return (1Y)+55.65%
    Total Return (3Y CAGR)+27.39%
    Return vs SPY (1Y)+42.43%
    Max Drawdown (1Y)-39.68%
    Max Drawdown (3Y)-56.03%
    Sharpe Ratio (1Y)0.78
    Correlation with SPY (1Y)0.26
    50-Day Average$2.70
    200-Day Average$2.45
    52-Week Range$1.65 to $3.19
    RSI (14 Days)56.5
    Average Volume (20 Days)984.45K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.27x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.27x
    Quick Ratio2.14x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 25.51% and return on assets is 17.38% over the last 12 months.

    Return on Equity (ROE)25.51%
    Return on Assets (ROA)17.38%
    Return on Capital Employed (ROCE)29.37%
    ROA (5Y Average)-11.68%
    ROIC (5Y Average)-46.11%
    Asset Turnover0.84x
    Inventory Turnover0.73x
    Receivables Turnover5.57x
    Cash Conversion Cycle479 days

    Taxes

    Income tax took 20.49% of pretax income over the last 12 months.

    Income Tax (TTM)$5.30M
    Effective Tax Rate20.49%

    Scores

    PLX has an Altman Z-Score of 5.84, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score5.84
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $84.69M over the last 12 months.

    Revenue$84.69M
    Revenue Growth (YoY)+36.96%
    Gross Profit$60.31M
    Operating Income$25.21M
    Pretax Income$25.85M
    Net Income$20.55M
    EBITDA$27.46M
    EBIT$25.85M
    Reported EPS (TTM)$0.25

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 68.12% of the $118.24M in total assets.

    Cash and Equivalents$22.04M
    Total Debt$0
    Net Cash$22.04M
    Net Cash Per Share$0.27
    Working Capital$68.64M
    Shareholder Equity$80.55M
    Book Value Per Share$1.00
    Total Assets$118.24M
    Total Liabilities$37.69M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.49M of capital spending, operating cash flow left $15.06M of free cash flow.

    Operating Cash Flow$17.56M
    Capital Expenditures$2.49M
    Free Cash Flow$15.06M
    FCF Per Share$0.19
    Depreciation and Amortization$1.62M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 29.76%, against a 5-year average of -13.56%.

    Gross Margin71.21%
    Operating Margin29.76%
    Pretax Margin30.52%
    Net Margin24.27%
    EBITDA Margin32.43%
    EBIT Margin30.52%
    FCF Margin17.79%
    Gross Margin (5Y Average)56.89%
    Operating Margin (5Y Average)-13.56%
    Net Margin (5Y Average)-19.52%

    Growth

    Revenue grew 3.45% a year over 3 years.

    Revenue Growth (3Y CAGR)+3.45%
    Revenue Growth (5Y CAGR)-3.46%
    Book Value Per Share Growth (2Y CAGR)+15.52%
    Tangible Book Per Share Growth (2Y CAGR)+15.52%

    Revenue and profit by year

    Dividends and Yields

    PLX does not pay a dividend. Its free cash flow yield is 6.47%.

    Earnings Yield8.62%
    FCF Yield6.47%
    Buyback Yield-1.81%
    Shareholder Yield-1.81%

    Stock Splits

    The last split was a 1-for-10 reverse split on Dec 20, 2019.

    Last Split DateDec 20, 2019
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 8 similar companies, PLX has the 7th highest P/S.

    P/S Ratio2.8x vs 7.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+36.95% vs +57.40% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 20.26% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+20.26%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PLX

    What is PLX's market cap?

    Protalix Biotherapeutics has a market cap of $255.49M. Its enterprise value, which adds debt and subtracts cash, is $233.45M.

    What is PLX's P/E ratio?

    Protalix Biotherapeutics has a trailing P/E ratio of 11.6x and a forward P/E of 11.9x.

    How many shares of PLX are outstanding?

    Protalix Biotherapeutics has 80.46M shares outstanding. The count is up 1.48% from a year earlier.

    Does PLX pay a dividend?

    No. Protalix Biotherapeutics does not pay a dividend.

    How much debt does PLX have?

    Protalix Biotherapeutics has $0 of total debt and $22.04M of cash and equivalents, a net cash position of $22.04M.